Altamira Therapeutics Ltd. (CYTOF): R&D Expense
Not updated since 2020-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
2.86M CHF
Year ended 2020-12-31
-47.0%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2020-12-31 | 2.86M CHF | -13.9% | 2021-03-31, From 2020-01-01 |
| 2019-12-31 | 3.33M CHF | -50.3% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | 6.69M CHF | -65.2% | 2021-03-31, From 2018-01-01 |
| 2017-12-31 | 19.21M CHF | n/a | 2020-04-16, From 2017-01-01 |